Deaths; cause of death (extensive list), age and sex
| Sex | Age | Causes of death | Periods | Deaths (number) |
|---|---|---|---|---|
| Total male and female | Total | C77 Secondary and unsp. m.n. lymph.. | 2022 | 0 |
| Total male and female | Total | C79 Secondary m.n. of other sites | 2022 | 0 |
| Total male and female | Total | G21 Secondary Parkinsonism | 2022 | 67 |
| Total male and female | Total | I15 Secondary hypertension | 2022 | 0 |
| Total male and female | 0 year | C77 Secondary and unsp. m.n. lymph.. | 2022 | 0 |
| Total male and female | 0 year | C79 Secondary m.n. of other sites | 2022 | 0 |
| Total male and female | 0 year | G21 Secondary Parkinsonism | 2022 | 0 |
| Total male and female | 0 year | I15 Secondary hypertension | 2022 | 0 |
| Total male and female | 1 to 4 years | C77 Secondary and unsp. m.n. lymph.. | 2022 | 0 |
| Total male and female | 1 to 4 years | C79 Secondary m.n. of other sites | 2022 | 0 |
| Total male and female | 1 to 4 years | G21 Secondary Parkinsonism | 2022 | 0 |
| Total male and female | 1 to 4 years | I15 Secondary hypertension | 2022 | 0 |
| Total male and female | 5 to 9 years | C77 Secondary and unsp. m.n. lymph.. | 2022 | 0 |
| Total male and female | 5 to 9 years | C79 Secondary m.n. of other sites | 2022 | 0 |
| Total male and female | 5 to 9 years | G21 Secondary Parkinsonism | 2022 | 0 |
| Total male and female | 5 to 9 years | I15 Secondary hypertension | 2022 | 0 |
| Total male and female | 10 to 14 years | C77 Secondary and unsp. m.n. lymph.. | 2022 | 0 |
| Total male and female | 10 to 14 years | C79 Secondary m.n. of other sites | 2022 | 0 |
| Total male and female | 10 to 14 years | G21 Secondary Parkinsonism | 2022 | 0 |
| Total male and female | 10 to 14 years | I15 Secondary hypertension | 2022 | 0 |
| Total male and female | 15 to 19 years | C77 Secondary and unsp. m.n. lymph.. | 2022 | 0 |
| Total male and female | 15 to 19 years | C79 Secondary m.n. of other sites | 2022 | 0 |
| Total male and female | 15 to 19 years | G21 Secondary Parkinsonism | 2022 | 0 |
| Total male and female | 15 to 19 years | I15 Secondary hypertension | 2022 | 0 |
| Total male and female | 20 to 24 years | C77 Secondary and unsp. m.n. lymph.. | 2022 | 0 |
| Total male and female | 20 to 24 years | C79 Secondary m.n. of other sites | 2022 | 0 |
| Total male and female | 20 to 24 years | G21 Secondary Parkinsonism | 2022 | 0 |
| Total male and female | 20 to 24 years | I15 Secondary hypertension | 2022 | 0 |
| Total male and female | 25 to 29 years | C77 Secondary and unsp. m.n. lymph.. | 2022 | 0 |
| Total male and female | 25 to 29 years | C79 Secondary m.n. of other sites | 2022 | 0 |
| Total male and female | 25 to 29 years | G21 Secondary Parkinsonism | 2022 | 0 |
| Total male and female | 25 to 29 years | I15 Secondary hypertension | 2022 | 0 |
| Total male and female | 30 to 34 years | C77 Secondary and unsp. m.n. lymph.. | 2022 | 0 |
| Total male and female | 30 to 34 years | C79 Secondary m.n. of other sites | 2022 | 0 |
| Total male and female | 30 to 34 years | G21 Secondary Parkinsonism | 2022 | 0 |
| Total male and female | 30 to 34 years | I15 Secondary hypertension | 2022 | 0 |
| Total male and female | 35 to 39 years | C77 Secondary and unsp. m.n. lymph.. | 2022 | 0 |
| Total male and female | 35 to 39 years | C79 Secondary m.n. of other sites | 2022 | 0 |
| Total male and female | 35 to 39 years | G21 Secondary Parkinsonism | 2022 | 0 |
| Total male and female | 35 to 39 years | I15 Secondary hypertension | 2022 | 0 |
| Total male and female | 40 to 44 years | C77 Secondary and unsp. m.n. lymph.. | 2022 | 0 |
| Total male and female | 40 to 44 years | C79 Secondary m.n. of other sites | 2022 | 0 |
| Total male and female | 40 to 44 years | G21 Secondary Parkinsonism | 2022 | 0 |
| Total male and female | 40 to 44 years | I15 Secondary hypertension | 2022 | 0 |
| Total male and female | 45 to 49 years | C77 Secondary and unsp. m.n. lymph.. | 2022 | 0 |
| Total male and female | 45 to 49 years | C79 Secondary m.n. of other sites | 2022 | 0 |
| Total male and female | 45 to 49 years | G21 Secondary Parkinsonism | 2022 | 0 |
| Total male and female | 45 to 49 years | I15 Secondary hypertension | 2022 | 0 |
| Total male and female | 50 to 54 years | C77 Secondary and unsp. m.n. lymph.. | 2022 | 0 |
| Total male and female | 50 to 54 years | C79 Secondary m.n. of other sites | 2022 | 0 |
| Total male and female | 50 to 54 years | G21 Secondary Parkinsonism | 2022 | 0 |
| Total male and female | 50 to 54 years | I15 Secondary hypertension | 2022 | 0 |
| Total male and female | 55 to 59 years | C77 Secondary and unsp. m.n. lymph.. | 2022 | 0 |
| Total male and female | 55 to 59 years | C79 Secondary m.n. of other sites | 2022 | 0 |
| Total male and female | 55 to 59 years | G21 Secondary Parkinsonism | 2022 | 0 |
| Total male and female | 55 to 59 years | I15 Secondary hypertension | 2022 | 0 |
| Total male and female | 60 to 64 years | C77 Secondary and unsp. m.n. lymph.. | 2022 | 0 |
| Total male and female | 60 to 64 years | C79 Secondary m.n. of other sites | 2022 | 0 |
| Total male and female | 60 to 64 years | G21 Secondary Parkinsonism | 2022 | 0 |
| Total male and female | 60 to 64 years | I15 Secondary hypertension | 2022 | 0 |
| Total male and female | 65 to 69 years | C77 Secondary and unsp. m.n. lymph.. | 2022 | 0 |
| Total male and female | 65 to 69 years | C79 Secondary m.n. of other sites | 2022 | 0 |
| Total male and female | 65 to 69 years | G21 Secondary Parkinsonism | 2022 | 2 |
| Total male and female | 65 to 69 years | I15 Secondary hypertension | 2022 | 0 |
| Total male and female | 70 to 74 years | C77 Secondary and unsp. m.n. lymph.. | 2022 | 0 |
| Total male and female | 70 to 74 years | C79 Secondary m.n. of other sites | 2022 | 0 |
| Total male and female | 70 to 74 years | G21 Secondary Parkinsonism | 2022 | 4 |
| Total male and female | 70 to 74 years | I15 Secondary hypertension | 2022 | 0 |
| Total male and female | 75 to 79 years | C77 Secondary and unsp. m.n. lymph.. | 2022 | 0 |
| Total male and female | 75 to 79 years | C79 Secondary m.n. of other sites | 2022 | 0 |
| Total male and female | 75 to 79 years | G21 Secondary Parkinsonism | 2022 | 11 |
| Total male and female | 75 to 79 years | I15 Secondary hypertension | 2022 | 0 |
| Total male and female | 80 to 84 years | C77 Secondary and unsp. m.n. lymph.. | 2022 | 0 |
| Total male and female | 80 to 84 years | C79 Secondary m.n. of other sites | 2022 | 0 |
| Total male and female | 80 to 84 years | G21 Secondary Parkinsonism | 2022 | 20 |
| Total male and female | 80 to 84 years | I15 Secondary hypertension | 2022 | 0 |
| Total male and female | 85 to 89 years | C77 Secondary and unsp. m.n. lymph.. | 2022 | 0 |
| Total male and female | 85 to 89 years | C79 Secondary m.n. of other sites | 2022 | 0 |
| Total male and female | 85 to 89 years | G21 Secondary Parkinsonism | 2022 | 20 |
| Total male and female | 85 to 89 years | I15 Secondary hypertension | 2022 | 0 |
| Total male and female | 90 to 94 years | C77 Secondary and unsp. m.n. lymph.. | 2022 | 0 |
| Total male and female | 90 to 94 years | C79 Secondary m.n. of other sites | 2022 | 0 |
| Total male and female | 90 to 94 years | G21 Secondary Parkinsonism | 2022 | 9 |
| Total male and female | 90 to 94 years | I15 Secondary hypertension | 2022 | 0 |
| Total male and female | 95 years or older | C77 Secondary and unsp. m.n. lymph.. | 2022 | 0 |
| Total male and female | 95 years or older | C79 Secondary m.n. of other sites | 2022 | 0 |
| Total male and female | 95 years or older | G21 Secondary Parkinsonism | 2022 | 1 |
| Total male and female | 95 years or older | I15 Secondary hypertension | 2022 | 0 |
| Male | Total | C77 Secondary and unsp. m.n. lymph.. | 2022 | 0 |
| Male | Total | C79 Secondary m.n. of other sites | 2022 | 0 |
| Male | Total | G21 Secondary Parkinsonism | 2022 | 43 |
| Male | Total | I15 Secondary hypertension | 2022 | 0 |
| Male | 0 year | C77 Secondary and unsp. m.n. lymph.. | 2022 | 0 |
| Male | 0 year | C79 Secondary m.n. of other sites | 2022 | 0 |
| Male | 0 year | G21 Secondary Parkinsonism | 2022 | 0 |
| Male | 0 year | I15 Secondary hypertension | 2022 | 0 |
| Male | 1 to 4 years | C77 Secondary and unsp. m.n. lymph.. | 2022 | 0 |
| Male | 1 to 4 years | C79 Secondary m.n. of other sites | 2022 | 0 |
| Male | 1 to 4 years | G21 Secondary Parkinsonism | 2022 | 0 |
| Male | 1 to 4 years | I15 Secondary hypertension | 2022 | 0 |
| Source: CBS. | ||||
Dataset is not available.
This table contains the number of deaths in the population of the Netherlands by underlying cause of death. The causes of death are shown according to the extensive list of 'three digit codes', by age and sex.
Since 2013 Statistics Netherlands is using Iris software for automatic coding for cause of death. This improved the international comparison of the data. The change in coding did cause a considerable shift in the statistic. Since 2013 the (yearly) ICD-10 updates are applied.
Data available from: 1996
Status of the figures:
All figures are final.
Changes as of December 11th 2023:
The final figures for 2022 have been added.
When will new figures be published?
The aim is to publish final figures for 2023 in the third quarter of 2024.
Description topics
- Deaths